Both in Biotechnology
Exelixis vs Halozyme Therapeutics
Over the past year EXEL returned +92.0% and HALO returned +91.5%; their daily moves had a correlation of 0.33.
EXEL +92.0% HALO +91.5%Growth of $1, one year, split-adjusted
| Metric | EXEL | HALO |
|---|---|---|
| Price | $72.75 | $130.34 |
| Market cap | $17.75B | $14.79B |
| Today | +0.61% | +1.34% |
| 1 month | +24.7% | +18.8% |
| 6 months | +49.4% | +96.4% |
| Year to date | +66.0% | +93.7% |
| 1 year | +91.1% | +96.9% |
| Revenue growth (YoY) | +10.2% | +47.7% |
| Gross margin | 96.0% | 83.5% |
| Net margin | 33.1% | 47.8% |
| P/E (TTM) | 20.1× | 35.8× |
| Price / sales | 7.1× | 8.9× |
| Net cash | $892.0M | -$1.92B |
| Dividend yield | — | — |
| Volatility (60d) | 25.7% | 27.9% |
| Short % of float | 11.4% | 12.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).